<DOC>
	<DOCNO>NCT00518427</DOCNO>
	<brief_summary>Primary objective : To assess quality Life ( QoL ) change treatment satisfaction real life situation patient Type 2 diabetes inadequately control combination oral antidiabetic drug ( OAD ) plus Neutral Protamine Hagedrone ( NHP ) insulin treatment switch insulin glargine . Secondary objective : To determine : change HbA1c , comparision incidence symptomatic hypoglycemia severe hypoglycemia introduction insulin glargine , change weight , change insulin dose .</brief_summary>
	<brief_title>Evaluate Quality Life Type 2 Diabetes , Before After Change Insuline Glargine</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>list inclusion exclusion criterion : Patients type 2diabetes inadequately control combination OAD + NPH insulin three month Stable OAD therapy least three month , accord follow specified daily dose : glibenclamide &gt; 3 , 5 mg , glipizid &gt; 5 mg , glimeperid &gt; 2mg , metformin &gt; 1000 mg , acarbose &gt; 150 mg HbA1c &gt; 7,0 % Ability perform QoL assessment Body Mass Indes : woman &lt; 30 men &lt; 32 Exlusion criterion : Autoimmune diabetes , define WHO Ongoing treatment tiasolidindion drug Retinopathy surgical treatment precede three month study entry require treatment within three month study entry Drug abuse Hypersensitivity insulin glagine excipients The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>